LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
This research is being done to determine if an image-based deep learning model (Sybil) can accurately predict the likelihood of future lung cancer based on chest computed tomography (CT) imaging from individuals with a family history of lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 25, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Massachusetts General Hospital
- Interventions being studied
- Diagnostic Test: CT scan; Other: Sybil
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- ≥18 years of age
- Positive family history of lung cancer (defined as):
- Has ≥1 first-degree relative OR
- Has ≥2 second-degree relatives with a diagnosis of non-small cell lung cancer or small cell lung cancer (NB: a first-degree relative = parent, sibling, or child, a second-degree relative = grandparent, blood-related aunt or uncle, grandchild, blood-related niece or nephew, half-sibling)
- Willing to provide images from at least one previously obtained CT Chest scan, if available.
\- None
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Massachusetts General HospitalBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2026. Always confirm current availability with the study team.